Ligand Pharmaceuticals Incorporated·Healthcare

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.

Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals

Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 119,309 shares of the biotechnology company's stock after selling 70,439 shares during the period. Aberdeen Group plc

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) Director John Kozarich sold 467 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.23, for a total value of $94,441.41. Following the transaction, the director directly owned 42,253 shares in the company, valued at

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $201.24, for a total value of $1,006,200.00. Following the transaction, the insider directly owned 41,382 shares in the company, valued at approximately
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.